Potential live vaccines for HIV

被引:7
|
作者
Burnett, MS [1 ]
Wang, N [1 ]
Hofmann, M [1 ]
Kitto, GB [1 ]
机构
[1] Univ Texas, Inst Mol & Cellular Biol, Dept Chem & Biochem, Austin, TX 78712 USA
基金
美国国家卫生研究院;
关键词
salmonella; reverse transcriptase; mucosal IgA;
D O I
10.1016/S0264-410X(00)00303-0
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Potential live vaccines for HIV were developed using an Lpp-OmpA system to target an HIV antigen, reverse transcriptase, or an immunodominant epitope of this enzyme, to the outer membrane of an attenuated strain of Salmonella SL3261. These live vaccines were administered orally to mice, and fecal IgA and helper T cell responses were measured. Results indicated a fecal IgA response specific to HIV reverse transcriptase, as well as a reverse transcriptase-specific helper T cell response, as measured by proliferation assays. Additionally, tests with the epitope vaccines showed a selective cytotoxic CD8 T cell response. These results suggest that this method of antigen targeting to the outer membrane of attenuated bacterial vectors is very promising not only for HIV vaccine development, but also for antigens from other viral or bacterial pathogens, which could be inserted into the Lpp-OmpA protein construct, to elicit mucosal IgA and T cell responses. (C) 2000 Published by Elsevier Science Ltd.
引用
收藏
页码:735 / 742
页数:8
相关论文
共 50 条
  • [21] Influence of Potential Protective Mechanisms on the Development of Live Rotavirus Vaccines
    Ward, Richard L.
    Clark, H. Fred
    Offit, Paul A.
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2010, 202 : S72 - S79
  • [22] HIV vaccine design: insights from live attenuated SIV vaccines
    Wayne C Koff
    Philip R Johnson
    David I Watkins
    Dennis R Burton
    Jeffrey D Lifson
    Kim J Hasenkrug
    Adrian B McDermott
    Alan Schultz
    Timothy J Zamb
    Rosanne Boyle
    Ronald C Desrosiers
    [J]. Nature Immunology, 2006, 7 : 19 - 23
  • [23] HIV vaccine design: insights from live attenuated SIV vaccines
    Koff, WC
    Johnson, PR
    Watkins, DI
    Burton, DR
    Lifson, JD
    Hasenkrug, KJ
    McDermott, AB
    Schultz, A
    Zamb, TJ
    Boyle, R
    Desrosiers, RC
    [J]. NATURE IMMUNOLOGY, 2006, 7 (01) : 19 - 23
  • [24] Live-attenuated HIV vaccines: How safe is safe enough?
    MurpheyCorb, M
    [J]. NATURE MEDICINE, 1997, 3 (01) : 17 - 18
  • [25] Live attenuated HIV vaccines: Predicting the tradeoff between efficacy and safety
    Blower, SM
    Koelle, K
    Kirschner, DE
    Mills, J
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (06) : 3618 - 3623
  • [26] Live-attenuated HIV vaccines: How safe is safe enough?
    Michael Murphey-Corb
    [J]. Nature Medicine, 1997, 3 : 17 - 18
  • [27] Probiotics: The Potential for a Live Microbicide to Prevent HIV
    Hemmerling, Anke
    Cohen, Craig R.
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2011, 56 (03) : E98 - E101
  • [28] Viral vectors as potential HIV-1 vaccines
    Schnell, MJ
    [J]. FEMS MICROBIOLOGY LETTERS, 2001, 200 (02) : 123 - 129
  • [29] PROJECTIONS FOR GLOBAL IMMUNIZATION PROGRAMS OF POTENTIAL HIV VACCINES
    KALLINGS, LO
    [J]. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1993, 6 (06): : 682 - 682
  • [30] Plant-made HIV vaccines and potential candidates
    Tremouillaux-Guiller, Jocelyne
    Moustafa, Khaled
    Hefferon, Kathleen
    Gaobotse, Goabaone
    Makhzoum, Abdullah
    [J]. CURRENT OPINION IN BIOTECHNOLOGY, 2020, 61 : 209 - 216